COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -21.79% | 0.25% | 31.82% | 45.22% | 42.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -21.79% | 0.25% | 31.82% | 45.22% | 42.11% |
| Cost of Revenue | 1.42% | -33.84% | -25.31% | -17.85% | -19.58% |
| Gross Profit | -45.63% | 184.87% | 898.42% | 913.78% | 570.78% |
| SG&A Expenses | 58.28% | -10.72% | 22.62% | 87.67% | 79.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.09% | 33.61% | 92.01% | 209.33% | 236.82% |
| Operating Income | -5.12% | -121.70% | -229.50% | -2,270.71% | -1,144.37% |
| Income Before Tax | 32.04% | -356.36% | -1,267.33% | -3,272.92% | -1,712.82% |
| Income Tax Expenses | -86.90% | 157.51% | 154.83% | 132.38% | 107.01% |
| Earnings from Continuing Operations | 32.34% | -1,200.70% | -4,160.78% | -1,811.79% | -814.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.34% | -1,200.70% | -4,160.78% | -1,811.79% | -814.71% |
| EBIT | -5.12% | -121.70% | -229.50% | -2,270.71% | -1,144.37% |
| EBITDA | -33.99% | -464.60% | -592.24% | -909.32% | -415.89% |
| EPS Basic | 26.68% | -272.96% | -112.35% | -118.42% | -163.02% |
| Normalized Basic EPS | -35.30% | -40.55% | 13.21% | 6.11% | -16.51% |
| EPS Diluted | 26.68% | -272.49% | -112.23% | -118.28% | -162.82% |
| Normalized Diluted EPS | -35.30% | -40.55% | 13.21% | 6.11% | -16.51% |
| Average Basic Shares Outstanding | 53.87% | 15.71% | 39.18% | 34.16% | 19.19% |
| Average Diluted Shares Outstanding | 53.87% | 15.71% | 39.18% | 34.16% | 19.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |